A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Inclusion Criteria:

• Cohort 1, only ambulatory participants:

• Able to walk without assistive aid

• 10-meter walk test (10MWT) <30 seconds

• NSAD ≥25

• Cohort 2, only non-ambulatory participants:

• 10MWT ≥30 seconds or unable to perform

• PUL 2.0 entry scale score ≥3

• Participants must possess 1 homozygous or 2 heterozygous pathogenic and/or likelypathogenic β-SG DNA gene mutations

• Able to cooperate with muscle testing

• Participants must have adeno-associated virus serotype rh74 (AAVrh74) antibodytiters <1:400 (that is, not elevated) as determined by AAVrh74 antibodyenzyme-linked immunosorbent assay.

Exclusion Criteria:

• Left ventricular ejection fraction < 40% or clinical signs and/or symptoms ofcardiomyopathy

• Forced vital capacity ≤40% of predicted value and/or requirement for nocturnalventilation

• Diagnosis of (or ongoing treatment for) an autoimmune disease and on activeimmunosuppressant treatment

• Presence of any other clinically significant illness or medical condition (otherthan LGMD2E/R4)

Other inclusion/exclusion criteria apply.